Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.15 - $16.81
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.36M
Market Cap
$740.82M
Enterprise Value$453.45M
Total Cash (Recent Filing)$36.28M
Total Debt (Recent Filing)$578.00K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 08, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.18
Shares Outstanding86,950,650
10 Day Avg. Volume1,255,275
30 Day Avg. Volume1,357,435
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)78.67
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit50.15
Enterprise Value/Ebitda-2.94
Forecast
1Y Price Target
$27.00Price Target Upside216.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Immunome News
PremiumCompany Announcements
Immunome’s 2024 Financial Results and Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Financial HealthCash and cash equivalents were reported at $217 million, which does not include gross proceeds of $172 million from the January 2025 financing.
Market OpportunityGSIs may represent an estimated $1.8B worldwide market opportunity for desmoid tumors, which are shifting away from surgery and traditional cancer therapies in favor of GSI's.
Pipeline ProgressAll pipeline assets remain on track, with the key catalyst, Ph 3 RINGSIDE trial results, expected in 2H25.
Bears Say
Commercial UncertaintyRegarding the commercial opportunity, management notes that this will be hard to answer until the profile is known, adding that if data replicates previous results, questions will answer themselves.
Competitive PressureThe lead asset varegacestat is a Phase 3 oral small molecule gamma-secretase inhibitor with one marketed competitor for rare progressing desmoid tumors, heading into a pivotal topline readout.
Financial SustainabilityAs of December 31st 2024, IMNM has $217.3M in cash and investments, excluding likely net proceeds of $161.6M from financing, providing an operating runway into March 2025.
---
Ownership Overview
1.61% Insiders
19.02% Mutual Funds
0.06% Other Institutional Investors
68.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $16.81 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $740.82M.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Mar 19, 2025. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.641 by -$0.469.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.64.
How many shares outstanding does Immunome have?
Immunome has 86,950,650 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.641. Following the earnings report the stock price went up 1.05%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
---
Immunome Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (216.90% Upside)
$27.00 (216.90% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 56.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-194.63%
Trailing 12-Months
Asset Growth
61.73%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
---
IMNM Stock 12 Month Forecast
Average Price Target
$27.00
▲(216.90% Upside)
Technical Analysis
Prothena
―
KalVista Pharmaceuticals
―
Dianthus Therapeutics
―
Trevi Therapeutics
―
Pharming Group
―
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-32.79%
reiterated a buy rating last month
Copying David Nierengarten's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -32.79% per trade.
---